Goldman Sachs has initiated coverage on Thermo Fisher Scientific Inc (TMO) with a Buy rating, marking its first assessment of the company. This action, taken on December 8, 2025, highlights the firm's research into Thermo Fisher's business dynamics and growth potential.
Headquartered in Waltham, Massachusetts, Thermo Fisher Scientific serves the scientific community through a diverse range of innovative products and services. The company operates within the Life Sciences Tools & Services industry, employing 125,000 full-time employees. Its offerings include reagents, instruments, and consumables essential for biological and medical research, drug and vaccine production, and disease diagnosis.
As of December 4, 2025, Thermo Fisher boasts a market capitalization of $213.5 billion, a price-to-earnings ratio of 32.52, and an earnings per share of 17.30. The company also has a dividend yield of 29.6%. Upcoming earnings reports are scheduled for July 21, 2026, with an expected EPS of $5.94 and revenue of $11.6 billion.
Analyst ratings like this one provide insights based on extensive research and financial modeling. However, they should be considered alongside other factors, including company fundamentals and market conditions. As new information emerges, analyst opinions may evolve, reflecting the dynamic nature of the market.